Friedemann Paul, MD, Charité-Universitätsmedizin Berlin, Berlin, Germany, discusses a study that evaluated the relationship between peripheral blood B-cell subsets and aquaporin-4 (AQP4) immunoglobulin G (IgG) titers and NMOSD attacks in participants of N-MOmentum (NCT02200770). Proinflammatory CD19+ B cells are considered a key driver of NMOSD attacks; however, less is known about the association of attacks with various B-cell subsets. Increased levels of B-cell subsets at the time of attack were observed in the placebo but not inebilizumab group, particularly in the plasma cells subset. Additionally, inebilizumab treatment was associated with reduction in AQP4-IgG in a subset of patients. This interview took place at the American Academy of Neurology Annual Meeting 2023 in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
